jeudi 19 mai 2016

Onco Actu du 19 mai 2016 (spécial ASCO)

1. Biologie

History of Dogs Tracked Through Contagious Canine Cancer [Phenomena: Not Exactly Rocket Science]

2.3 Etiologie - OGM

National Academy of Sciences Report on GMOs [Science-Based Medicine]

2.6 Etiologie - Environnement

Glyphosate And Cancer [In the Pipeline]

3.1 Tabac

Healthcare costs nosedive when smokers quit [Reuters]

3.6 Prévention - Activité physique

Why reducing cancer risk is more than ‘just a walk in the park’ [Cancer Research UK]

Well: Exercise Tied to Lower Risk for 13 Types of Cancer [NY Times]

5. Traitements

A tinkerer takes on cancer by hijacking the tiny garbage trucks inside every cell [STAT]

5.12 Immunothérapies

Three Generations of Cancer Immunotherapies [ESMO]

5.2 Pharma

Novartis breast cancer drug set to take on Pfizer's Ibrance [Reuters]

5.3.4 Traitements - AMM (FDA, EMA)

FDA approves new, targeted treatment for bladder cancer [FDA]

F.D.A. Approves an Immunotherapy Drug for Bladder Cancer [NY Times]

U.S. FDA approves Roche's immunotherapy for bladder cancer [Reuters] ASCO (général) - Industriels

ASCO 2016 to Feature Latest Oncology Research from Bayer [Bayer]

ARIAD Announces Data Presentations at the 2016 ASCO Annual Meeting [Ariad]

Myriad to Present New Research at the 2016 ASCO Annual Meeting [Myriad]

Foundation Medicine Announces Presentations at ASCO [Foundation Medicine]

Juno Therapeutics to Highlight Advancing Immuno-oncology Portfolio at the 2016 American Society of Clinical Oncology Annual Meeting [Juno]

ASCO Data Underscore Lilly's Diverse Oncology Pipeline and Portfolio [Lilly]

Breadth and Depth of Bristol-Myers Squibb’s Immuno-Oncology Clinical Development Program to be Showcased at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting [BMS]

Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting [Pfizer]

Pfizer to Showcase Diverse and Growing Oncology Portfolio at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting [Pfizer]

Amgen Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients [Amgen]

Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting [Novartis] ASCO (général) - Académiques

Early Palliative Care Provides Important Benefits for Family Caregivers of Patients With Cancer [ASCO]

Precision Medicine Yields Better Outcomes for Patients in Phase I Clinical Trials [ASCO]

Precision medicine approach to cancer improves on older methods: study [Reuters]

5.5.10 ASCO (hémato)

Stem Cell Transplant Remains Important for Multiple Myeloma, Even in Novel Agent Era [ASCO]

5.5.2 ASCO (sein)

Pfizer's Ibrance delays breast cancer progression: study [Reuters]

5.5.4 ASCO (immunothérapies)

Pfizer cancer drug shows promise in combo with Merck's Keytruda [Reuters]

5.5.5 ASCO (gastro-intestinal)

Side where colon cancer begins affects survival, finds study [STAT]

Left vs. Right: Primary Tumor Location Predicts Survival in Metastatic Colorectal Cancer [ASCO]

Colon cancers 'more deadly on right' [BBC News]

5.5.6 ASCO (peau-mélanome)

New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting [Merck]

PD-1 Inhibitor Pembrolizumab Provides Long-Term Survival Benefit for Patients With Advanced Melanoma [ASCO]

Skin cancer: Drug gives '40% melanoma survival' [BBC News]

German Merck, Pfizer immunotherapy shows promise in rare skin cancer [Reuters]

Merck, Bristol drugs show longer survival for deadly cancers [Reuters]

5.5.8 ASCO (poumon)

Two-Year Overall Survival Data from Two Pivotal Opdivo® (nivolumab) Trials Demonstrate Sustained Benefit In Patients with Advanced Non-Small Cell Lung Cancer [BMS]

6.1 Observation

Thousands of patients left waiting as Wales misses ‘critical’ cancer treatment target [Cancer Research UK]

Impoverished background affects cancer risk later in life [Cancer Research UK]

6.10 Politiques

Colombia to Novartis: Lower the price of your cancer drug, or else [STAT]

Deal still possible in Colombia-Novartis cancer drug talks : minister [Reuters]